Johnson & Johnson

Key Takeaways:Lung cancer patients with advanced EGFR-mutated NSCLC now have a new treatment option with the European Commission's approval of RYBREVANT® (amivantamab) in...

Key Takeaways:Janssen's BALVERSA® (erdafitinib) has been approved by the European Commission for the treatment of metastatic urothelial carcinoma with FGFR3 alterations. This approval...

Johnson & Johnson has entered a definitive agreement to acquire V-Wave Ltd., a company focused on innovative treatments for heart failure. This acquisition is...

Lung cancer patients have new hope with the FDA's recent approval of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech,...

10 Key Takeaways from "Understanding Value-Based Pricing in Medical Devices: Aligning Cost with Patient Outcomes and Healthcare Efficiency":Shift from Traditional Pricing Models: Value-based...

Heart pumps, particularly the Impella CP with SmartAssist devices from Abiomed, have recently come under scrutiny as the U.S. Food and Drug Administration (FDA)...

Awareness of the risks tied to Megadyne electrode pads is being raised by the Food and Drug Administration (FDA) and Health Canada. The FDA...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of RYBREVANT® for treating adult...

Myeloma treatment expanded with the US Food and Drug Administration (FDA) and the FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research and...

Fresenius Kabi, an operating company of Fresenius specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, and...

Despite the typical summer slowdown, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has shown no signs of reducing...

Johnson & Johnson (NYSE: JNJ) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration...

Pricing negotiations for Johnson & Johnson’s (J&J) top-selling drugs—Stelara, Xarelto, and Imbruvica are underway with Medicare, but the pharmaceutical giant does not foresee a...

Multiple myeloma patients with relapsed or lenalidomide-refractory disease, after receiving one prior line of therapy, showed statistically significant and clinically meaningful improvement in overall...

Johnson & Johnson has received traditional approval from the U.S. Food and Dug Administration (FDA) and full approval from the European Commission (EC) for...